STAT3通路致癌性激活驱动自然杀伤/T细胞淋巴瘤PD-L1表达
该研究对171例外周T细胞淋巴瘤(PTCL)和结外NK/T细胞淋巴瘤(NKTL)进行188个JAK/STAT通路基因的靶向捕获测序,发现73%样本存在272个非同义体细胞突变,STAT3突变在NKTL中占21%。新型STAT3突变可增强STAT3磷酸化及转录活性,其中p.E616K通过激活STAT3与PD-L1基因启动子强结合诱导PD-L1表达,STAT3激活与NKTL肿瘤PD-L1表达显著相关。
要点
- 在171例PTCL和NKTL中,73%样本检出272个非同义体细胞突变,STAT3和TP53突变各占15%。
- NKTL中STAT3突变高发(21%),新型STAT3突变可增强STAT3磷酸化及转录活性。
- p.E616K通过激活STAT3与PD-L1启动子强结合诱导PD-L1表达,STAT3激活与NKTL肿瘤PD-L1表达显著相关。
核心结论
- STAT3激活赋予NKTL高PD-L1表达,可能促进肿瘤免疫逃逸。
- PD-1/PD-L1抗体联合STAT3抑制剂可能是NKTL、也可能用于PTCL的有前景的治疗方法。
研究设计与样本
- 对171例PTCL和NKTL病例进行188个JAK/STAT通路基因的靶向捕获测序。
- 在NKTL细胞系中验证STAT3突变对STAT3磷酸化、转录活性及PD-L1表达的影响。
- 在NKTL肿瘤中分析STAT3激活与PD-L1表达的相关性。
主要发现
- 在73%的样本中鉴定出101个基因的272个非同义体细胞突变,包括258个单核苷酸变异和14个插入或缺失。
- 复发性突变最常见于STAT3和TP53(各15%),其次为JAK3和JAK1(各6%)及SOCS1(4%)。
- 在NKTL中观察到STAT3突变高发(21%)。
- 新型STAT3突变(p.D427H、p.E616G、p.E616K和p.E696K)在无细胞因子条件下增加STAT3磷酸化和STAT3转录活性。
- p.E616K通过激活的STAT3与PD-L1基因启动子强结合诱导PD-L1表达。
临床怎么用
- 作者认为,PD-1/PD-L1抗体联合STAT3抑制剂可能是NKTL、也可能用于PTCL的有前景的治疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mature T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and extranodal NK/T-cell lymphoma (NKTL), represent a heterogeneous group of non-Hodgkin lymphomas with dismal outcomes and limited treatment options. To determine the extent of involvement of the JAK/STAT pathway in this malignancy, we performed targeted capture sequencing of 188 genes in this pathway in 171 PTCL and NKTL cases. A total of 272 nonsynonymous somatic mutations in 101 genes were identified in 73% of the samples, including 258 single-nucleotide variants and 14 insertions or deletions. Recurrent mutations were most frequently located in STAT3 and TP53 (15%), followed by JAK3 and JAK1 (6%) and SOCS1 (4%). A high prevalence of STAT3 mutation (21%) was observed specifically in NKTL. Novel STAT3 mutations (p.D427H, E616G, p.E616K, and p.E696K) were shown to increase STAT3 phosphorylation and transcriptional activity of STAT3 in the absence of cytokine, in which p.E616K induced programmed cell death-ligand 1 (PD-L1) expression by robust binding of activated STAT3 to the PD-L1 gene promoter. Consistent with these findings, PD-L1 was overexpressed in NKTL cell lines harboring hotspot STAT3 mutations, and similar findings were observed by the overexpression of p.E616K and p.E616G in the STAT3 wild-type NKTL cell line. Conversely, STAT3 silencing and inhibition decreased PD-L1 expression in STAT3 mutant NKTL cell lines. In NKTL tumors, STAT3 activation correlated significantly with PD-L1 expression. We demonstrated that STAT3 activation confers high PD-L1 expression, which may promote tumor immune evasion. The combination of PD-1/PD-L1 antibodies and STAT3 inhibitors might be a promising therapeutic approach for NKTL, and possibly PTCL.
引用
- Song TL, Nairismägi ML, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018. PMID: 30054295. doi:10.1182/blood-2018-01-829424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。